IBEX vs NVEC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IBEX exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial stability and operational efficiency. The stock is currently trading at $27.49, which is essentially at its Graham Number ($27.9) and significantly below its growth-based intrinsic value of $88.79. Despite a bearish technical trend and recent insider selling by the CEO, the combination of a low P/E (9.13), high ROE (33.65%), and robust earnings growth (45.6% YoY) presents a compelling value opportunity.
NVEC presents a dichotomy of pristine operational efficiency and concerning valuation/dividend sustainability. While the Piotroski F-Score of 4/9 indicates stable health and the balance sheet is exceptionally strong with negligible debt and massive liquidity, the stock is significantly overvalued relative to its Graham Number ($28.52). The most critical concern is the unsustainable dividend payout ratio of 136.99%, which suggests the current yield is not supported by earnings. Despite strong margins and revenue growth, bearish insider sentiment and technical trends suggest a potential price correction.
Compare Another Pair
Related Comparisons
IBEX vs NVEC: Head-to-Head Comparison
This page compares IBEX Limited (IBEX) and NVE Corporation (NVEC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.